British company Oxford Biomedica has said the Serum Institute of India (SII) will invest $68 million in it to help fund the development of a plant that manufactures Covid-19 shots, Reuters reports.

SII — the world’s largest vaccine manufacturer by volume — and Oxford Biomedica both produce AstraZeneca’s Covid-19 vaccine.

Oxford Biomedica said it would use the funds to develop the fallow area at its Oxbox plant into a manufacturing space expected to come online in mid-2023.

The Oxbox plant currently makes Covid-19 shots, and the new space is expected to include a capacity to produce viral vector-based products including vaccines, Biomedica said.

The Serum Institute of India — AFP/File
The Serum Institute of India — AFP/File

Opinion

Editorial

Budget presser
Updated 14 Jun, 2026

Budget presser

If the FBR falters, the government will find itself in hot water sooner rather than later.
Muharram precautions
14 Jun, 2026

Muharram precautions

WITH Muharram due to start next week, the authorities have already begun annual exercises to ensure that the ...
Blood bequests
14 Jun, 2026

Blood bequests

WORLD Blood Donor Day offers a moment of “gratitude, advocacy and renewed commitment” for thalassaemia patients...
Sustainable path?
Updated 13 Jun, 2026

Sustainable path?

The FY27 budget is the first clear signal that the government is ready to transition from stabilisation to growth.
Prioritising education
13 Jun, 2026

Prioritising education

THOUGH the improvement in the country’s literacy rate may be slight, as highlighted by the Economic Survey, it ...
Poverty’s rise
13 Jun, 2026

Poverty’s rise

AS attention turns to the government’s plans for the coming fiscal year, one set of figures deserves particular...